PRCT Stock Recent News

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.43 per share a year ago.

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential in urology where its Aquablation technology has many potential indications. The company should rebound throughout the year on increased consumable usage and new deployments of its device through IDNs.

Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno - President and CEO Kevin Waters - EVP and CFO Matt Bacso - VP, IR and Business Operations Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - Cowen Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Richard Newitter - Truist Nathan Treybeck - Wells Fargo Matthew Mishan - KeyBanc Operator Good morning, and welcome to the PROCEPT BioRobotics First Quarter 2023 Earnings Conference Call.

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.39 per share a year ago.

PROCEPT BioRobotics Corporation (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at 12:45 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.